15th – 16th October 2019

Kerry Hotel Pudong, Shanghai


Antonio Lee

Antonio Lee

Global Head of Business Development , MEDIPOST

Dr. Antonio Lee is the Global Head of Business Development at MEDIPOST (KOSDAQ: 078160; Seoul, Korea) and also serves as the CEO and Managing Director at MEDIPOST America Inc., a wholly-owned U.S. subsidiary of MEDIPOST.

Since 2011, Dr. Lee has been involved in the global commercialization and clinical development strategy, regulatory affairs and marketing of human Umbilical Cord Blood (hUCB)-derived Stem Cell technology and products developed by MEDIPOST, including the World’s First regulatory-approved allogeneic stem cell product - CARTISTEM®, for the treatment of knee Osteoarthritis (OA).

Dr. Lee also serves as the Chair of the Board of Directors for MEDIPOST’s North Asian Joint-Venture entities – ‘ORLIFE Pharmaceuticals, Shandong, China’ and ‘EVASTEM Therapeutics, Tokyo, Japan’